Develops oral therapies that target the small intestine to treat obesity, diabetes, and rare diseases.
Buy
Sign up to view historical trading trends and place an offer.
Sell
Understand share pricing, list anonymously, and benefit from transparent fees.
Overview
Syntis Bio is developing oral therapies that target the small intestine to treat obesity, diabetes, and rare diseases. Their proprietary technology uses a mussel-inspired polymer to deliver therapeutic agents directly to the gastrointestinal tract, enabling more effective and accessible treatments for complex conditions.
Syntis Bio Funding
Sign up to gain insights into Syntis Bio funding history, including the funding round, time period, and amount raised.
| Financing Round | Date | Amount | Price per share | Valuation |
|---|---|---|---|---|
| Round | Date | Amount | PPS | Valuation |
| Series A | Jun 17, 2025 | 6M | ||
| Series A | Jun 17, 2025 | 25M | ||
| Series Seed | Jan 17, 2023 | 4M | ||
| Series Seed | Aug 03, 2022 | 11M |
Access the PPS, Valuation details, and a wealth of other data by signing up. Source: Nasdaq Private Market
Buy
Sign up to view historical trading trends and place an offer.
Sell
Understand share pricing, list anonymously, and benefit from transparent fees.
Syntis Bio Management Team
Investors
Apollo Labs
Cerity Partners Ventures
W. R. Berkley Corporation
Bold Capital Partners
Mansueto Investments
Safar Partners
Cerberus Ventures
Portal Innovations
Colorcon Ventures
Woori Venture Partners
Syntis Bio Valuations & Financials
View real-time NPM data on Syntis Bio stock including daily Syntis Bio stock price estimates, valuation history, and historical share price information. Access Syntis Bio financing rounds, secondary trade levels, cap table data, and private company comparable transactions. Use NPM's private company valuation database to track Syntis Bio pricing across six independent market signals. Looking for private company due diligence data sources on Syntis Bio? Get in touch to learn more.
Similar Companies
like Syntis Bio
FAQ
We have answers
Syntis Bio stock does not trade on public stock exchanges. Syntis Bio stock is considered a private security and you need to be an accredited investor to trade shares. To invest in Syntis Bio stock you can either buy shares directly through the company or work with a secondary trading marketplace like Nasdaq Private Market.
Learn more about the secondary market for private company shares on the investors page.
Syntis Bio Stock does not trade on public stock exchanges. In order to sell Syntis Bio shares you need to work directly with the company or with a secondary trading marketplace like Nasdaq Private Market. NPM has more than a decade of experience helping sell shares on the private market to our network of institutional investors.
Learn more about NPM services for selling privately held stock on the Employee Shareholders page.
Read more about how to sell private company stock on the private secondary market:
Syntis Bio does not have a publicly available stock price because it is privately held and not traded on public stock exchanges. Through the NPM Data and Intelligence database from Nasdaq Private Market, you can view Syntis Bio share price and other valuable private market data.
Read more about secondary market private company stock prices:
There is no ticker symbol for Syntis Bio stock because it is a private company. Private companies do not have ticker symbols like public companies, they are identified primarily by using the company ‘street’ name or legal name.
Nasdaq Private Market currently works with employees, ex-employees, and other company investors. In order to sell Syntis Bio stock you need to receive the company’s approval, which Nasdaq Private Market manages on your behalf.
Learn more about selling privately held stock on the Employee Shareholders page.
Read more about how to sell shares of a private company and eligibility for selling privately held stock:
Currently, Nasdaq Private Market only works with accredited entities and institutional investors to purchase private company stock. In order to invest in Syntis Bio stock, you need to be an accredited entity or institutional investor.
Learn more about the Nasdaq Private Market tool kit for investors on the Investor Trading page.
Once you buy or sell, stock share ownership must transfer before funds are wired. With Nasdaq Private Market, clients leverage our patent-pending Transfer and Settlement technology which streamlines and manages transfer activity from match to settlement.
To learn more about private company stock Transfer and Settlement, check out the Transfer and Settlement page.
Syntis Bio is a private company and has not had an IPO. There is currently no Syntis Bio IPO price. Get started to begin exploring the Nasdaq Private Market Data and Intelligence database and gain access to actionable data related to Syntis Bio IPO.
Learn more about Data and Intelligence private company stock data for institutional investors on the on the NPM Data and Intelligence Product Page.
